Targeted Therapies for Hepatocellular Carcinoma
TLDR
Identification of oncogenes that mediate tumor progression, and trials that monitor their products as biomarkers, might lead to personalized therapy; reagents that interfere with signaling pathways required for HCC progression might be used to treat selected populations, and thereby maximize the efficacy and cost benefit.About:
This article is published in Gastroenterology.The article was published on 2011-05-01 and is currently open access. It has received 402 citations till now. The article focuses on the topics: Sorafenib & Targeted therapy.read more
Citations
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet,Michel Ducreux,Riccardo Lencioni,Adrian M. Di Bisceglie,Jean-Francois J. DuFour,Tim F. Greten,Eric Raymond,Tania Roskams,Vincenzo Mazzaferro,Jordi Bruix,Massimo Colombo,Andrew X. Zhu +11 more
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Journal ArticleDOI
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro,Carlos Gomez-Martin,Manuel de la Mata,Mercedes Iñarrairaegui,Elena Garralda,Pilar Barrera,Jose I Riezu-Boj,Esther Larrea,Carlos Alfaro,Pablo Sarobe,Juan José Lasarte,Jose Luis Perez-Gracia,Ignacio Melero,Ignacio Melero,Jesús Prieto,Jesús Prieto +15 more
TL;DR: Tremelimumab safety profile and antitumor and antiviral activity, in patients with advanced HCC developed on HCV-induced liver cirrhosis, support further investigation.
Journal ArticleDOI
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
TL;DR: In this paper, a review outlines pathogenic mechanisms that seem to be common to both hepatitis B virus and hepatitis C virus and suggest innovative approaches to the prevention and treatment of HCC.
Journal ArticleDOI
Mechanisms of HBV-induced hepatocellular carcinoma
TL;DR: HBV-related HCCs may arise on non-cirrhotic livers, further supporting the notion that HBV plays a direct role in liver transformation by triggering both common and etiology specific oncogenic pathways in addition to stimulating the host immune response and driving liver chronic necro-inflammation.
References
More filters
Journal ArticleDOI
Medicare and cost-effectiveness analysis.
TL;DR: It is argued that policymakers could avert the impending financial crisis facing Medicare by incorporating cost-effectiveness analysis into a comprehensive strategy to allocate health care resources more rationally.
Journal ArticleDOI
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo ☆
Pippa Newell,Sara Toffanin,Augusto Villanueva,Derek Y. Chiang,Derek Y. Chiang,Beatriz Minguez,Laia Cabellos,Radoslav Savic,Yujin Hoshida,Yujin Hoshida,Kiat Hon Lim,Pedro Melgar-Lesmes,Steven Yea,Judit Peix,Kemal Deniz,M. Isabel Fiel,Swan N. Thung,Clara Alsinet,Victoria Tovar,Vincenzo Mazzaferro,Jordi Bruix,Sasan Roayaie,Myron Schwartz,Scott L. Friedman,Josep M. Llovet,Josep M. Llovet +25 more
TL;DR: Ras activation results from several molecular alterations, such as methylation of tumor suppressors and amplification of oncogenes (B-raf).
Journal ArticleDOI
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
Victoria Tovar,Clara Alsinet,Augusto Villanueva,Yujin Hoshida,Derek Y. Chiang,Manel Solé,Swan N. Thung,Susana Moyano,Sara Toffanin,Beatriz Minguez,Laia Cabellos,Judit Peix,Myron Schwartz,Vincenzo Mazzaferro,Jordi Bruix,Josep M. Llovet,Josep M. Llovet +16 more
TL;DR: In this article, an integrative molecular dissection of the IGF axis was conducted in a cohort of 104 HCCs analyzing gene and miRNA expression, structural aberrations, and protein activation.
Journal ArticleDOI
Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Richard S. Finn,Yoon-Koo Kang,Mary F. Mulcahy,Blase N. Polite,Ho Yeong Lim,Ian Walters,Christine Baudelet,Demetrios Manekas,Joong-Won Park +8 more
TL;DR: Brivanib had a manageable safety profile and is one of the first agents to show promising antitumor activity in advanced HCC patients treated with prior sorafenib.
Journal ArticleDOI
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis.
Kenneth K. Tanabe,Antoinette Lemoine,Dianne M. Finkelstein,Hiroshi Kawasaki,Tsutomu Fujii,Raymond T. Chung,Gregory Y. Lauwers,Yakup Kulu,Alona Muzikansky,Darshini Kuruppu,Michael Lanuti,Jonathan M. Goodwin,Daniel Azoulay,Bryan C. Fuchs +13 more
TL;DR: The EGF gene polymorphism genotype is associated with risk for development of hepatocellular carcinoma in liver cirrhosis through modulation of EGF levels through inhibition fragment-length polymorphism.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more